Pseudomonas aeruginosa lipopolysaccharide serotype O11 (P. aeruginosa LPS O11)

Pseudomonas aeruginosa lipopolysaccharide (LPS) serotype O11 is a critical surface component and major virulence factor of the Gram-negative bacterium Pseudomonas aeruginosa [7, 9]. LPS is composed of three domains: the hydrophobic lipid A, a core oligosaccharide, and the distal O-antigen (O-polysaccharide), the latter of which determines the O11 serotype specificity [8, 13]. This molecule plays a vital role in maintaining the structural integrity of the bacterial outer membrane and protecting the pathogen from host immune responses, including complement-mediated killing [2, 7]. In clinical settings, serotype O11 is frequently associated with severe, multidrug-resistant infections such as ventilator-associated pneumonia and sepsis, often linked to highly virulent strains that secrete the ExoU cytotoxin [20, 21]. Therapeutic strategies targeting this molecule include the development of serotype-specific monoclonal antibodies, such as Panobacumab (KBPA101), which enhance bacterial clearance through opsonophagocytosis and complement activation [1, 5, 11]. Additionally, the lipid A component of the LPS is the primary target for polymyxin antibiotics, which disrupt the bacterial membrane [3, 7].

Other names

O11 antigenP. aeruginosa O11 LPSPseudomonas aeruginosa O11 O-antigenIATS O11 LPSO-specific antigen O11

Drugs targeting this molecule work through distinct mechanisms: monoclonal antibodies like Panobacumab bind to the O-antigen to facilitate opsonophagocytosis by neutrophils and activate the complement system [1, 5, 6], while polymyxin antibiotics bind to the lipid A region to displace divalent cations and disrupt the integrity of the bacterial outer membrane [3, 7].